The financials
Pulse Biosciences, Inc. by the numbers
Pulse Biosciences, Inc. (PLSE) reported revenue of $401K in Q1 2026 (quarter ended March 31, 2026). That came with a gross margin of 7.7% and net loss of $19M. For the full year FY2025, revenue was $350K and net income −$73M. Its largest product in 2022-Q2 was System Products at $209K, 79% of the disclosed total, just ahead of Cycle Units Products at 21%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $401K | $0 | n/a |
| Gross profit | $31K | $0 | n/a |
| Operating income | −$19M | −$18M | n/a |
| Net income | −$19M | −$17M | n/a |
| Product | Revenue | Share |
|---|---|---|
| System Products | $209K | 79% |
| Cycle Units Products | $56K | 21% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2023Total $0.00
Segment Latestyear on year
- Cycle Units Products$0.00$0.00year on year --
- System Products$0.00$0.00year on year --
Medical Instruments & Supplies
Ranks #15 of 27 by Smart Score